Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
44,41 USD | -2,12% | -6,45% | +24,82% |
30/05 | Crinetics Pharmaceuticals, Inc. nomina Robert M. Cuddihy come Vicepresidente senior degli Affari medici | CI |
24/05 | CRINETICS PHARMACEUTICALS, INC. : Morgan Stanley conferma il rating Buy | ZM |
Attività
Numero di dipendenti: 290
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100,0
%
| 5 | 100,0 % | 4 | 100,0 % | -15,28% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States and Australia
100,0
%
| 5 | 100,0 % | 4 | 100,0 % | -15,28% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Stephen Betz
FOU | Founder | 58 | 01/01/08 |
Scott Struthers
FOU | Founder | 62 | 01/01/08 |
Marc Wilson
DFI | Director of Finance/CFO | 44 | 01/01/18 |
Dana Pizzuti
CTO | Chief Tech/Sci/R&D Officer | 68 | 30/09/22 |
Matt McDowell
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jeff Knight
COO | Chief Operating Officer | 52 | 30/08/21 |
Chris Robillard
PRN | Corporate Officer/Principal | - | 21/03/22 |
Garlan Adams
LAW | General Counsel | - | 16/06/21 |
Michael Monahan
LAW | General Counsel | - | 01/06/18 |
Brian Russell
PRN | Corporate Officer/Principal | - | 01/03/22 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Wendell Wierenga
CHM | Chairman | 76 | 01/10/15 |
Matthew Fust
BRD | Director/Board Member | 59 | 01/02/18 |
Director/Board Member | 71 | 03/09/20 | |
Caren Deardorf
BRD | Director/Board Member | 59 | 11/03/22 |
Director/Board Member | 60 | 03/01/22 | |
Weston Nichols
BRD | Director/Board Member | 39 | 01/02/18 |
Scott Struthers
FOU | Founder | 62 | 01/01/08 |
Stephanie Okey
BRD | Director/Board Member | 64 | 15/07/19 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 78 859 510 | 75 716 938 ( 96,01 %) | 0 | 96,01 % |
Coordinate società
Crinetics Pharmaceuticals, Inc.
6055 Lusk Boulevard
92121, San Diego
+858 450 6464
http://www.crinetics.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+24,82% | 3,5 Mrd | |
+43,36% | 54,63 Mrd | |
-5,31% | 39,92 Mrd | |
+14,75% | 26,86 Mrd | |
-12,56% | 26,22 Mrd | |
-22,45% | 18,78 Mrd | |
+25,12% | 12,21 Mrd | |
+0,04% | 12,16 Mrd | |
+26,04% | 11,94 Mrd | |
-11,83% | 10,74 Mrd |
- Borsa valori
- Azioni
- Azione CRNX
- Società Crinetics Pharmaceuticals, Inc.